Corporate Actions
Sai Life Sciences rises on completion of second phase expansion at Bidar facility

20-Jun-25   14:49 Hrs IST
The new phase, which became operational on 19 June 2025, adds approximately 91 kL of production capacity. This marks the second and final phase of the total planned capacity addition of approximately 195 kL at the facility, as disclosed in the company's prospectus.

With this addition, the total installed capacity at Unit IV now stands at approximately 640 kL. The expanded facility is equipped to manufacture Registered Starting Materials (RSM), intermediates, and Active Pharmaceutical Ingredients (APIs) for both clinical and commercial applications.

Hyderabad-based Sai Life Sciences is a leading global contract research, development, and manufacturing organization (CRDMO) that partners with innovator pharmaceutical and biotech companies to accelerate the discovery, development, and commercialization of new medicines. The company offers integrated solutions spanning medicinal chemistry, process development, clinical and commercial manufacturing, and advanced technology platforms.

The company's consolidated net profit surged 57.3% to Rs 88.27 crore on a 31.9% increase in revenue from operations to Rs 579.51 crore in Q4 March 2025 over Q4 March 2024.

Powered by Capital Market - Live News

Attention Investors: Stock Brokers can accept securities as margin from clients only by way of pledge in the depository system w.e.f. September 1, 2020. || Update your mobile number & email Id with your stock broker/depository participant and receive OTP directly from depository on your email id and/or mobile number to create pledge. || Pay 20% upfront margin of the transaction value to trade in cash market segment. || Investors may please refer to the Exchange's Frequently Asked Questions (FAQs) issued vide circular reference NSE/INSP/45191 dated July 31, 2020 and NSE/INSP/45534 dated August 31, 2020 and other guidelines issued from time to time in this regard. || Check your Securities /MF/ Bonds in the consolidated account statement issued by NSDL/CDSL every month.|| KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.|| No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.